Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Dasatinib + PRI-724|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Dasatinib||Sprycel||BMS-354825||ABL Inhibitor (pan) 8 BCR-ABL Inhibitor 27 BTK inhibitor 24 CSF1R Inhibitor 25 DDR1 Inhibitor 8 DDR2 inhibitor 7 KIT Inhibitor 51 PDGFR Inhibitor (Pan) 27 SRC Inhibitor 29 TNK2 Inhibitor 6||Sprycel (dasatinib) is an inhibitor of the SRC-family of protein kinases, BCR-ABL, and ABL, and has additional activity against other kinases including KIT, DDR1/2, PDGFRA/B, and EPHA2, which prevents cell growth (PMID: 25709401, PMID: 25284748, PMID: 18797457, PMID: 23942795). Sprycel (dasatinib) is FDA approved for both Philadelphia chromosome positive adult and pediatric chronic myelogenous leukemia and adult acute lymphoblastic leukemia (FDA.gov).|
|PRI-724||CTNNB1 Inhibitor 26||PRI-724 is a Wnt signaling pathway inhibitor which antagonistically inhibits the recruiting of beta-catenin with its coactivator CBP, thereby inhibiting tumor growth (PMID: 31550723).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT01606579||Phase Ib/II||Cytarabine + PRI-724 Dasatinib + PRI-724 PRI-724||Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies||Completed||USA||0|